Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close.About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.
Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Standard BioToolsLABNGS:LABbiotech investing
LAB
The Conversation (0)
Stockpiles Continue to Deliver High- Grade Gold Assays

Stockpiles Continue to Deliver High- Grade Gold Assays

(TheNewswire) VANCOUVER TheNewswire - September 3, 2026, Providence Gold Mines Inc. ("Providence" or the "Company") further to the July 29th, 2026, news release, the Company is very pleased to provide gold assay results of the second stockpile trenching sample program from the Tarantula mine at... Keep Reading...
Brixton Metals Drills 6,199 g/t Silver over 1.00 m including 0.50 m of 12,386 g/t Silver in Hole 432 at its Langis Project in Ontario

Brixton Metals Drills 6,199 g/t Silver over 1.00 m including 0.50 m of 12,386 g/t Silver in Hole 432 at its Langis Project in Ontario

Hole 399: 4.60 m of 503 g/t Silver Hole 408: 7.00 m of 290 g/t Silver including 2.00 m of 958 g/t Silver Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the "Company" or "Brixton") is pleased to report additional silver results from 33 holes at its wholly owned Langis Silver Project,... Keep Reading...
Lahontan Drills 10.7m Grading 1.81 g/t Au and 64.8 g/t Ag, Completes Santa Fe Mine Stockpile Drill Program

Lahontan Drills 10.7m Grading 1.81 g/t Au and 64.8 g/t Ag, Completes Santa Fe Mine Stockpile Drill Program

Lahontan Gold Corp. (TSXV:LG,OTC:LGCXF, OTCQB:LGCXF, FSE:Y2F) (the "Company" or "Lahontan") is pleased to announce additional results from its 2026 Sonic core drilling program at the Santa Fe Mine Project. The Sonic drilling campaign is evaluating historic heap leach pads and stockpiles to... Keep Reading...
Cascadia Drills 82.69 m of 1.12% Cu and 0.64 g/t Au at the Carmacks Project, Yukon

Cascadia Drills 82.69 m of 1.12% Cu and 0.64 g/t Au at the Carmacks Project, Yukon

Cascadia Minerals Ltd. ("Cascadia") (TSX-V: CAM) (OTCQB: CAMNF) is pleased to announce the results of five additional drill holes from its fully-funded 2026 exploration program at the road-accessible Carmacks copper-gold project in central Yukon. These results continue to expand mineralization... Keep Reading...
Gold Runner Exploration Samples up to 25,306 Grams per Ton Silver with 11.22 Grams per Ton Gold for a Gold Equivalent of 12.7 Ounces per Ton in New 350 Meter Gold Stack Trend on the 100% Controlled Golden Girl Property, Golden Triangle, B.C.

Gold Runner Exploration Samples up to 25,306 Grams per Ton Silver with 11.22 Grams per Ton Gold for a Gold Equivalent of 12.7 Ounces per Ton in New 350 Meter Gold Stack Trend on the 100% Controlled Golden Girl Property, Golden Triangle, B.C.

Gold Runner Exploration Inc. (CSE: GRUN) (FSE: CE70) ("Gold Runner" or the "Company") is pleased to announce initial results for samples assayed up to 25,306 gt Ag (grams per ton Silver) with 11.2 gt Au (grams per ton Gold), or 12.7 ounces per ton Gold Equivalent, from the newly discovered 350... Keep Reading...
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September... Keep Reading...
BriaCell Therapeutics (TSX:BCT)

BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation

Clinical-stage immuno-oncology company BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) has achieved a “key genetic engineering milestone” with ‘Melanoma’, its personalized whole-cell melanoma immunotherapy vaccine candidate.The achievement allows the vaccine’s program to proceed towards clinical... Keep Reading...
Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received... Keep Reading...
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

(TheNewswire) Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the... Keep Reading...
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0... Keep Reading...
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2026

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind,... Keep Reading...

Latest News

More News

Interactive Chart

Latest Press Releases

VanadiumCorp Announces Grant of Stock Options

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Miivo AI Inc. Renews SOC 2 Type II Certification

Institutional Entitlement Offer and Placement Successfully Completed

Related News

copper investing

Top 5 Canadian Mining Stocks This Week: Decade Resources Doubles with 100 Percent Gain

gold investing

Editor's Picks: Gold, Silver Bounce Back After Warsh Scare, Oil Prices Break US$90

battery metals investing

VanadiumCorp Announces Grant of Stock Options

rare earth investing

Ionic and USSM Plan US$100 Million Rare Earths Recycling Plant in Missouri

Institutional Entitlement Offer and Placement Successfully Completed

gold investing

Aurum Adds More High-Grade Gold at Boundiali’s BST1 Deposit

agriculture investing

A$1.1Million Placement to Fund Critical Minerals Strategyand Unlock Value from Potash